APYX
Apyx Medical Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-45/100
Last price
2.55
▼ 0.06 (2.12%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
2.60
Day high
2.63
Day low
2.53
Volume
129.27K
Market cap
$107.21M
P/E (TTM)
—
52W range
2.32 – 5.08
Trailing performance
Returnvs SPY
1W
-2.12%
-4.1%
1M
-16.56%
-17.7%
3M
-39.55%
-44.1%
6M
-32.13%
-50.3%
YTD
-27.29%
-41.5%
1Y
+6.49%
-9.9%
3Y
-20.47%
-102.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on APYX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
5.71M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 30, 26 | WALDMAN LAWRENCE J Director |
CONVERSION | 12.00K | $22.56K | Indirect |
| Jun 15, 26 | ROMAN SHAWN DAVID Chief Operating Officer |
CONVERSION | 15.00K | $48.45K | Indirect |
| Jun 11, 26 | VIZIRGIANAKIS STAVROS G Director |
STOCK | 450.00K | $0 | Direct |
| Mar 13, 26 | CITRONOWICZ MOSHE Officer |
CONVERSION | 37.00K | $66.60K | Direct |
| Jan 27, 26 | ROMAN SHAWN DAVID Chief Operating Officer |
CONVERSION | 12.00K | $21.60K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CITRONOWICZ MOSHE |
Officer | 493.50K | Conversion of Exercise of derivative security |
ROMAN SHAWN DAVID |
Chief Operating Officer | — | Conversion of Exercise of derivative security |
VIZIRGIANAKIS STAVROS G |
Director | 2.20M | Stock Award(Grant) |
WALDMAN LAWRENCE J |
Director | — | Conversion of Exercise of derivative security |
Fundamentals
Market cap$107.21M
Enterprise value$119.65M
Revenue (TTM)$58.41M
Gross profit$37.09M
EBITDA$-2.75M
Net income$-8.63M
EPS (TTM)$-0.20
Free cash flow$-9.63M
Total cash$27.62M
Total debt$39.63M
Book value / share$0.25
Shares outstanding42.12M
Float30.50M
Short % of float0.55%
Dividend yield0.00%
Beta (5Y)1.45
Valuation & profitability ratios
Trailing P/E—
Forward P/E-10.11
PEG ratio0.59
Price / sales—
Price / book10.06
EV / revenue2.05
EV / EBITDA-43.43
Gross margin63.50%
Operating margin-13.01%
Profit margin-14.78%
Return on equity-90.69%
Return on assets-3.71%
Debt / equity357.35
Current ratio5.68
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $52.84M | $48.10M | $52.35M | $44.51M | +9.9% |
| Operating revenue | $52.84M | $48.10M | $52.35M | $44.51M | +9.9% |
| Cost of revenue | $19.80M | $18.74M | $18.59M | $15.38M | +5.6% |
| Gross profit | $33.04M | $29.36M | $33.76M | $29.13M | +12.5% |
| Research & development | $3.37M | $5.08M | $5.44M | $4.54M | -33.6% |
| Selling, general & admin | $36.12M | $43.13M | $48.27M | $48.15M | -16.3% |
| Total operating expense | $39.49M | $48.20M | $53.71M | $52.69M | -18.1% |
| Operating income | -$6.45M | -$18.84M | -$19.95M | -$23.56M | +65.8% |
| Net interest income | -$4.48M | -$4.30M | -$1.56M | $142.00K | -4.2% |
| Pre-tax income | -$10.84M | -$23.31M | -$21.28M | -$22.91M | +53.5% |
| Tax provision | $270.00K | $252.00K | -$2.43M | $367.00K | +7.1% |
| Net income | -$11.21M | -$23.46M | -$18.71M | -$23.18M | +52.2% |
| Net income to common | -$11.21M | -$23.46M | -$18.71M | -$23.18M | +52.2% |
| Basic EPS | -0.27 | -0.66 | -0.54 | -0.67 | +59.1% |
| Diluted EPS | -0.27 | -0.66 | -0.54 | -0.67 | +59.1% |
| EBIT | -$5.25M | -$17.40M | -$18.80M | -$22.90M | +69.9% |
| EBITDA | -$4.59M | -$16.80M | -$18.11M | -$22.01M | +72.7% |
| Basic shares | 41.09M | 35.54M | 34.62M | 34.52M | +15.6% |
| Diluted shares | 41.09M | 35.54M | 34.62M | 34.52M | +15.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $31.74M | $31.74M | $43.65M | $10.19M | -0.0% |
| Cash & short-term investments | $31.74M | $31.74M | $43.65M | $10.19M | -0.0% |
| Accounts receivable | $16.78M | $15.48M | $14.02M | $10.60M | +8.4% |
| Inventory | $8.60M | $7.56M | $9.92M | $11.80M | +13.7% |
| Total current assets | $58.47M | $56.44M | $70.36M | $42.97M | +3.6% |
| Property, plant & equipment | $6.62M | $6.74M | $7.15M | $7.59M | -1.8% |
| Total assets | $66.84M | $64.84M | $79.24M | $51.77M | +3.1% |
| Total current liabilities | $11.70M | $10.72M | $12.74M | $11.85M | +9.1% |
| Long-term debt | $34.85M | $33.89M | $33.19M | — | +2.8% |
| Total debt | $39.34M | $38.76M | $38.50M | $796.00K | +1.5% |
| Total liabilities | $52.01M | $50.51M | $52.32M | $13.98M | +3.0% |
| Retained earnings | -$89.12M | -$77.91M | -$54.45M | -$35.73M | -14.4% |
| Shareholder equity | $14.54M | $14.21M | $26.70M | $37.58M | +2.3% |
| Working capital | $46.77M | $45.72M | $57.62M | $31.12M | +2.3% |
| Net tangible assets | $14.54M | $14.21M | $26.70M | $37.58M | +2.3% |
| Shares issued | 41.79M | 37.79M | 34.64M | 34.60M | +10.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$11.11M | -$23.56M | -$18.85M | -$23.28M | +52.9% |
| Depreciation & amortisation | $655.00K | $599.00K | $692.00K | $890.00K | +9.3% |
| Stock-based compensation | $2.00M | $4.01M | $5.11M | $6.70M | -50.1% |
| Change in working capital | -$1.59M | -$1.25M | $5.54M | -$5.22M | -27.8% |
| Operating cash flow | -$8.00M | -$18.05M | -$5.25M | -$20.28M | +55.7% |
| Capital expenditure | -$1.11M | -$722.00K | -$533.00K | -$1.01M | -54.3% |
| Investing cash flow | -$1.11M | -$722.00K | $6.73M | -$1.01M | -54.3% |
| Financing cash flow | $9.58M | $6.75M | $32.17M | $217.00K | +42.0% |
| Free cash flow | -$9.12M | -$18.77M | -$5.78M | -$21.29M | +51.4% |
| End cash position | $31.74M | $31.74M | $43.65M | $10.19M | -0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $13.88M | $12.49M | $19.16M | $12.88M | $11.37M | +11.2% |
| Operating revenue | $13.88M | $12.49M | $19.16M | $12.88M | $11.37M | +11.2% |
| Cost of revenue | $5.01M | $4.57M | $7.17M | $4.58M | $4.29M | +9.8% |
| Gross profit | $8.87M | $7.92M | $12.00M | $8.30M | $7.08M | +11.9% |
| Research & development | $793.00K | $765.00K | $944.00K | $801.00K | $824.00K | +3.7% |
| Selling, general & admin | $9.88M | $8.07M | $11.04M | $8.33M | $8.83M | +22.5% |
| Total operating expense | $10.68M | $8.84M | $11.99M | $9.13M | $9.66M | +20.8% |
| Operating income | -$1.81M | -$911.00K | $11.00K | -$832.00K | -$2.57M | -98.2% |
| Net interest income | -$1.14M | -$1.13M | -$1.17M | -$1.12M | -$1.11M | -1.7% |
| Pre-tax income | -$2.95M | -$2.00M | -$1.15M | -$1.88M | -$3.69M | -47.4% |
| Tax provision | $124.00K | $143.00K | $94.00K | $78.00K | $49.00K | -13.3% |
| Net income | -$3.24M | -$2.11M | -$1.30M | -$1.98M | -$3.78M | -53.8% |
| Net income to common | -$3.24M | -$2.11M | -$1.30M | -$1.98M | -$3.78M | -53.8% |
| Basic EPS | -0.07 | -0.05 | -0.03 | -0.05 | -0.09 | -40.0% |
| Diluted EPS | -0.07 | -0.05 | -0.03 | -0.05 | -0.09 | -40.0% |
| EBIT | -$1.55M | -$631.00K | $261.00K | -$464.00K | -$2.30M | -146.3% |
| EBITDA | -$1.36M | -$429.00K | $482.00K | -$300.00K | -$2.16M | -216.6% |
| Basic shares | 43.85M | 42.16M | 42.16M | 39.68M | 41.98M | +4.0% |
| Diluted shares | 43.85M | 42.16M | 42.16M | 39.68M | 41.98M | +4.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $27.62M | $31.14M | $31.74M | $25.14M | $29.30M | -11.3% |
| Cash & short-term investments | $27.62M | $31.14M | $31.74M | $25.14M | $29.30M | -11.3% |
| Accounts receivable | $13.61M | $12.76M | $16.78M | $12.99M | $11.25M | +6.7% |
| Inventory | $10.75M | $9.54M | $8.60M | $9.14M | $8.19M | +12.7% |
| Total current assets | $53.16M | $54.80M | $58.47M | $48.79M | $49.91M | -3.0% |
| Property, plant & equipment | $6.14M | $6.35M | $6.62M | $6.76M | $6.55M | -3.3% |
| Total assets | $61.07M | $63.02M | $66.84M | $57.37M | $58.19M | -3.1% |
| Total current liabilities | $9.35M | $9.45M | $11.70M | $10.98M | $10.57M | -1.0% |
| Long-term debt | $35.33M | $35.09M | $34.85M | $34.61M | $34.37M | +0.7% |
| Total debt | $39.63M | $39.46M | $39.34M | $39.21M | $39.08M | +0.4% |
| Total liabilities | $49.98M | $49.94M | $52.01M | $51.28M | $50.73M | +0.1% |
| Retained earnings | -$94.47M | -$91.23M | -$89.12M | -$87.82M | -$85.84M | -3.6% |
| Shareholder equity | $10.66M | $12.83M | $14.54M | $5.85M | $7.25M | -16.9% |
| Working capital | $43.80M | $45.35M | $46.77M | $37.81M | $39.35M | -3.4% |
| Net tangible assets | $10.66M | $12.83M | $14.54M | $5.85M | $7.25M | -16.9% |
| Shares issued | 42.12M | 41.87M | 41.79M | 37.82M | 37.79M | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$3.07M | -$2.14M | -$1.24M | -$1.96M | -$3.74M | -43.4% |
| Depreciation & amortisation | $196.00K | $202.00K | $221.00K | $164.00K | $132.00K | -3.0% |
| Stock-based compensation | $1.07M | $312.00K | $500.00K | $530.00K | $520.00K | +244.2% |
| Change in working capital | -$2.08M | $789.00K | -$2.76M | -$2.72M | $1.29M | -364.3% |
| Operating cash flow | -$3.49M | -$572.00K | -$2.53M | -$3.54M | -$1.23M | -510.1% |
| Capital expenditure | -$66.00K | -$60.00K | -$275.00K | -$519.00K | -$265.00K | -10.0% |
| Investing cash flow | -$66.00K | -$60.00K | -$275.00K | -$519.00K | -$265.00K | -10.0% |
| Financing cash flow | -$5.00K | $83.00K | $9.48M | $45.00K | $25.00K | -106.0% |
| Free cash flow | -$3.56M | -$632.00K | -$2.81M | -$4.05M | -$1.50M | -462.7% |
| End cash position | $27.62M | $31.14M | $31.74M | $25.14M | $29.30M | -11.3% |
Options analytics
Put / call volume
1.33
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
-1.8% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+6.2%
Puts bid over calls
Call volume
3
Contracts, this expiry
Put volume
4
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
2.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.08 | -0.07 | +14.6% |
| Mar 2026 | -0.11 | -0.05 | +54.6% |
| Dec 2025 | -0.06 | -0.03 | +46.4% |
| Sep 2025 | -0.10 | -0.05 | +51.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.09 | 6 | $13.29M | +3.2% |
| Next quarter | -0.05 | 6 | $19.73M | +3.0% |
| Current year | -0.27 | 6 | $59.41M | +12.4% |
| Next year | -0.25 | 6 | $65.97M | +11.1% |
Analyst targets & ownership
Mean target$6.50
High target$8.00
Low target$6.00
Implied upside155.40%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy2 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders13.55%
Held by institutions50.58%
Institutions holding75
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.65
-3.91% from price
SMA 20
2.81
-9.54% from price
SMA 50
3.15
-19.29% from price
SMA 100
3.69
-31.07% from price
SMA 200
3.70
-31.15% from price
EMA 12
2.67
-4.78% from price
EMA 26
2.85
-10.76% from price
EMA 50
3.11
-18.22% from price
RSI (14)
36.2
Neutral
MACD (12,26,9)
-0.18
Hist -0.01
ATR (14)
0.18
7.12% of price
Realised vol 30D
63.2%
Annualised
Bollinger upper
3.24
20, 2σ
Bollinger lower
2.39
20, 2σ
50 / 200 cross
Death
3.15 vs 3.70
Trend bias
Below 200
-31.15%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.26
More volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
63.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-49.6%
Peak to trough
Max drawdown 5Y
-95.0%
Peak to trough
ATR 14
0.18
7.12% of price
Beta (reported)
1.45
5Y monthly, from filing
Short interest
Shares short
218.05K
Prior 230.35K
Change vs prior
-5.3%
Shorts covering
% of float
0.55%
Normal
% of shares out
0.52%
Against total outstanding
Days to cover
1.7
Liquid
Float
30.50M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 29, 26 | Maxim Group | INITIATED | — | Buy |
| Jul 13, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| Mar 11, 26 | Craig-Hallum | MAINTAINED | Buy | Buy |
| Mar 11, 26 | BTIG | UPGRADE | Neutral | Buy |
| Dec 16, 25 | Roth Capital | INITIATED | — | Buy |
| Nov 12, 25 | Citizens | UPGRADE | Market Perform | Market Outperform |
| Oct 17, 24 | BTIG | INITIATED | — | Neutral |
| Sep 16, 24 | JMP Securities | MAINTAINED | — | Market Perform |
| Nov 10, 23 | Stephens & Co. | MAINTAINED | Overweight | Overweight |
| Aug 11, 23 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Jul 14, 23 | Stephens & Co. | INITIATED | — | Overweight |
| Jun 15, 23 | Lake Street | MAINTAINED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-29
Corporate Changes & Voting Matters
8-K · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-24
Proxy Statements
DEF 14A · 2026-06-26
Corporate Changes & Voting Matters
8-K · 2026-06-17
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-06-01
Corporate Changes & Voting Matters
8-K · 2026-05-21
Headlines
Maxim Initiates Apyx Medical at Buy With $6 Price Target
MT Newswires · 8d ago
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality
GlobeNewswire · 8d ago
Cold Plasma Market Forecasts Growth from $3.32B (2025) to $8.45B by 2032, Profiling Nordson Corporation, Apyx Medical, Plasmatreat & Enercon Industries
GlobeNewswire · 13d ago
Cold Plasma Market Forecasts Growth from $167.8M (2025) to $495.9M by 2033, Profiling Apyx Medical, Neoplas Med, Adtec Healthcare & 5 Other Key Players
GlobeNewswire · 22d ago
Apyx Medical (APYX) Q2 2026 Earnings Call Transcript
Motley Fool · 54d ago
Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring
MarketBeat · 56d ago
Apyx Medical Corp (APYX) (Q2 2026) Earnings Call Highlights: Revenue Surges 22% on Power Lipo ...
GuruFocus.com · 61d ago
Apyx Medical (APYX) Reports Q2 Loss, Beats Revenue Estimates
Zacks · 61d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.